(Q34456149)

2 August 2017

1 reference

title

The taxoids. Comparative clinical pharmacology and therapeutic potential (English)

1 reference

2 August 2017

1 reference

E A Eisenhauer

1

1 reference

2 August 2017

J B Vermorken

series ordinal

2

1 reference

2 August 2017

publication date

1 January 1998

1 reference

2 August 2017

1 reference

2 August 2017

volume

55

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

5-30

1 reference

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

2 August 2017

cites work

1 reference

12 December 2020

Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.

1 reference

12 December 2020

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

1 reference

12 December 2020

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

12 December 2020

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

1 reference

12 December 2020

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC

1 reference

12 December 2020

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1 reference

12 December 2020

Preclinical evaluation of docetaxel (Taxotere).

1 reference

12 December 2020

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

12 December 2020

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

1 reference

12 December 2020

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

12 December 2020

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

12 December 2020

Taxol administered as a 120 hour infusion

1 reference

12 December 2020

Docetaxel: an active drug for squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results

1 reference

12 December 2020

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

1 reference

12 December 2020

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

12 December 2020

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer

1 reference

12 December 2020

Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

1 reference

12 December 2020

Phase I trial of taxol given as a 3-hour infusion every 21 days

1 reference

12 December 2020

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

12 December 2020

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

1 reference

12 December 2020

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

12 December 2020

Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of taxol.

1 reference

12 December 2020

Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

12 December 2020

High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial

1 reference

12 December 2020

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions

1 reference

12 December 2020

Taxol is active in platinum-resistant endometrial adenocarcinoma

1 reference

12 December 2020

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

1 reference

12 December 2020

Paclitaxel plus carboplatin in the treatment of ovarian cancer

1 reference

12 December 2020

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

12 December 2020

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study

1 reference

12 December 2020

Phase I trial of taxol in patients with advanced cancer

1 reference

12 December 2020

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

1 reference

12 December 2020

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

12 December 2020

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

1 reference

12 December 2020

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

12 December 2020

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

12 December 2020

Taxol: a review of its preclinical in vivo antitumor activity

1 reference

12 December 2020

Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer

1 reference

12 December 2020

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

1 reference

12 December 2020

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function

1 reference

12 December 2020

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

1 reference

12 December 2020

Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

12 December 2020

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

12 December 2020

A phase II trial of taxol in metastatic melanoma

1 reference

12 December 2020

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

1 reference

12 December 2020

Taxanes: a new class of antitumor agents.

1 reference

12 December 2020

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion

1 reference

12 December 2020

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

1 reference

12 December 2020

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group

1 reference

12 December 2020

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

12 December 2020

The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.

1 reference

12 December 2020

Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort

1 reference

12 December 2020

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

12 December 2020

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

12 December 2020

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors

1 reference

12 December 2020

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Taxol metabolism and disposition in cancer patients

1 reference

12 December 2020

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

1 reference

12 December 2020

Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus

1 reference

12 December 2020

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

1 reference

12 December 2020

Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer

1 reference

12 December 2020

A phase II study of taxol in patients with malignant melanoma

1 reference

12 December 2020

Salvage chemotherapy with paclitaxel for recurrent primary brain tumors

1 reference

12 December 2020

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

12 December 2020

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

1 reference

12 December 2020

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer

1 reference

12 December 2020

1 reference

12 December 2020

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas

1 reference

12 December 2020

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

1 reference

12 December 2020

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

1 reference

12 December 2020

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

12 December 2020

Primary therapy of multiple myeloma with paclitaxel (taxol)

1 reference

12 December 2020

Current and future trials of Taxol (paclitaxel) in head and neck cancer.

1 reference

12 December 2020

Single agent paclitaxel in advanced squamous cell head and neck carcinoma

1 reference

12 December 2020

Phase I study of taxol using a 5-day intermittent schedule

1 reference

12 December 2020

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

1 reference

12 December 2020

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

12 December 2020

Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience

1 reference

12 December 2020

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

12 December 2020

A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.

1 reference

12 December 2020

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

1 reference

12 December 2020

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

12 December 2020

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

1 reference

12 December 2020

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro

1 reference

12 December 2020

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

12 December 2020

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

1 reference

12 December 2020

Peripheral neurotoxicity induced by docetaxel.

1 reference

12 December 2020

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

12 December 2020

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer

1 reference

12 December 2020

A phase II trial of paclitaxel (Taxol�) as first line treatment in advanced breast cancer

1 reference

12 December 2020

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

12 December 2020

Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer

1 reference

12 December 2020

Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer

1 reference

12 December 2020

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

12 December 2020

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

12 December 2020

Promotion of microtubule assembly in vitro by taxol

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

Phase II study of paclitaxel in patients with recurrent malignant glioma.

1 reference

12 December 2020

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

12 December 2020

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group

1 reference

12 December 2020

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study

1 reference

12 December 2020

Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.

1 reference

12 December 2020

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

12 December 2020

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

12 December 2020

Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

1 reference

12 December 2020

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

12 December 2020

Phase I trial of Taxotere: five-day schedule

1 reference

12 December 2020

Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma

1 reference

12 December 2020

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

12 December 2020

Paclitaxel-induced neuropathy

1 reference

12 December 2020

Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain

1 reference

12 December 2020

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule

1 reference

12 December 2020

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

10.2165/00003495-199855010-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1027431780

0 references

1 reference